{"id":111997,"date":"2024-07-25T14:46:23","date_gmt":"2024-07-25T13:46:23","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=insight&#038;p=111997"},"modified":"2024-07-29T17:31:46","modified_gmt":"2024-07-29T16:31:46","slug":"trending-at-asco2024","status":"publish","type":"insight","link":"https:\/\/touchoncology.com\/insight\/trending-at-asco2024\/","title":{"rendered":"Trending at #ASCO2024"},"content":{"rendered":"<p><span style=\"font-weight: 400\">The annual ASCO2024 meeting was packed as always with the latest trial data and treatment advances in oncology. For those unable to visit Chicago this year, Twitter provides a glimpse into the impactful presentations and data. Here are some of the top trending abstracts and topics from this year\u2019s meeting:<\/span><\/p>\n<h1>CheckMate-9DW trial<\/h1>\n<p><span style=\"font-weight: 400\">First results from the preplanned interim analysis <\/span><span style=\"font-weight: 400\">from the phase III <\/span><span style=\"font-weight: 400\">CheckMate-9DW trial (<\/span><span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04039607?term=nivolumab%20%2B%20checkmate%209DW&amp;rank=1\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">NCT04039607<\/span><\/a><\/span><span style=\"font-weight: 400\"><span style=\"color: #0000ff\">)<\/span> showed <\/span><span style=\"font-weight: 400\">nivolumab in combination with ipilimumab demonstrate a <\/span><span style=\"font-weight: 400\">significant overall survival benefit <\/span><span style=\"font-weight: 400\">compared to <\/span><b>lenvatinib or sorafenib<\/b><span style=\"font-weight: 400\"> in the 1st-line treatment of patients with <\/span><span style=\"font-weight: 400\">unresectable hepatocellular carcinoma (HCC).<\/span><\/p>\n<p><span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/234365\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">The full abstract is available here<\/span><\/a>.<\/span><\/p>\n<h1><span style=\"font-weight: 400\">DESTINY-Breast06<\/span><\/h1>\n<p><span style=\"font-weight: 400\">\u00a0Results from the DESTINY-Breast06 <\/span><span style=\"font-weight: 400\">phase 3 trial<\/span><span style=\"font-weight: 400\"> found trastuzumab deruxtecan demonstrated clinically meaningful progression-free survival (PFS) improvement in patients with hormone receptor (HR)\u2013positive, HER2-low metastatic breast cancer following endocrine therapy.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">The trial results establish <\/span><span style=\"font-weight: 400\">trastuzumab deruxtecan<\/span><span style=\"font-weight: 400\"> \u201cas an effective new treatment option for patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one line or more of endocrine-based therapy and no prior chemotherapy,\u201d according to study presenter Giuseppe Curigliano, MD, PhD, of the University of Milan and European Institute of Oncology in Italy.<\/span><\/p>\n<p><span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/238015\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">View the full abstract here.<\/span><\/a><\/span><\/p>\n<h1><span style=\"font-weight: 400\">LAURA trial<\/span><\/h1>\n<p><span style=\"font-weight: 400\">Results from the phase III LAURA trial demonstrated that osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non-small-cell lung cancer (NSCLC) following definitive chemoradiotherapy.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Lead author Suresh Ramalingham commented: \u201cThere are currently no approved targeted treatments specifically for unresectable stage III <\/span><i><span style=\"font-weight: 400\">EGFR<\/span><\/i><span style=\"font-weight: 400\">-mutated NSCLC. The LAURA study showed a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with unresectable <\/span><i><span style=\"font-weight: 400\">EGFR<\/span><\/i><span style=\"font-weight: 400\">-mutated NSCLC following definitive chemoradiotherapy. With the superior efficacy results along with the robust magnitude of benefit in the LAURA study, osimertinib provides a solution to a large unmet need for this patient population. These data suggest that osimertinib will become a new standard of care for patients with unresectable stage III <\/span><i><span style=\"font-weight: 400\">EGFR<\/span><\/i><span style=\"font-weight: 400\">-mutated NSCLC following definitive chemoradiotherapy\u201d.<\/span><\/p>\n<p><span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/234898\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">View the full abstract here<\/span><\/a><\/span><\/p>\n<h1><span style=\"font-weight: 400\">ASC4FIRST<\/span><\/h1>\n<p><span style=\"font-weight: 400\">Primary results from the phase III ASC4FIRST study demonstrated significantly superior efficacy and excellent safety and tolerability for asciminib compared to investigator-selected tyrosine kinase inhibitors in patients with newly diagnosed chronic myeloid leukemia (CML).<\/span><\/p>\n<p>\u201c[A]sciminib has the potential to become a therapy of choice for patients with newly diagnosed CML-chronic phase,\u201d commented Timothy P. Hughes, MD, of the South Australian Health and Medical Research Institute and the University of Adelaide in Australia.<\/p>\n<p><span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/231667\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">View the full abstract here.<\/span><\/a><span style=\"font-weight: 400\">\u00a0<\/span><\/span><\/p>\n<p><b><i>Disclosures<\/i><\/b><i><span style=\"font-weight: 400\">: This article was created by the touchONCOLOGY team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https:\/\/chat.openai.com\/chat.) The content was developed and edited by human editors. No funding was received in the publication of this article.<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400\">Don\u2019t get to follow<strong> @touchONCOLOGY<\/strong> on X to hear about our latest content.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Take a look at the touchONCOLOGY conference highlights from ASCO 2024<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The annual ASCO2024 meeting was packed as always with the latest trial data and treatment advances in oncology.<\/p>\n","protected":false},"featured_media":113377,"template":"","class_list":["post-111997","insight","type-insight","status-publish","has-post-thumbnail","hentry","vocabulary_1-breast-cancer","vocabulary_1-gastrointestinal-cancers","vocabulary_1-haematological-malignancies","vocabulary_1-lung-cancer"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/insight\/111997"}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/insight"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/insight"}],"version-history":[{"count":6,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/insight\/111997\/revisions"}],"predecessor-version":[{"id":113762,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/insight\/111997\/revisions\/113762"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/113377"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=111997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}